

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 6B4517) proposing that the food additive regulations be amended to provide for the safe use of diethylene glycol as a component of a pulp bleaching medium used in the manufacture of paper and paperboard intended for use in contact with food.

**FOR FURTHER INFORMATION CONTACT:** Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 Ct. SW., Washington, DC 20204, 202-418-3095.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of September 30, 1996 (61 FR 51118), FDA announced that a food additive petition (FAP 6B4517) had been filed by MacMillan Bloedel, Ltd., c/o Camplong & Associates, Inc., P.O. Box 238, Schomberg, Ontario L0G 1T0, Canada. The filing notice stated that the petition proposed to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of diethylene glycol as a pulp bleaching agent for paper and paperboard intended for use in contact with food. Upon further review, FDA has determined that the petition proposed the use of diethylene glycol as a component of a pulp bleaching medium used in the manufacture of food-contact paper and paperboard. MacMillan Bloedel, Ltd. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: April 10, 1998.

**Laura M. Tarantino,**

*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 98-12541 Filed 5-11-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 98F-0195]

#### **Vanetta S.p.A.; Filing of Food Additive Petition (Animal Use) Menadione Nicotinamide Bisulfite**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Vanetta S.p.A. has filed a petition to allow the use of menadione

nicotinamide bisulfite in swine diets as a source of vitamin K activity and niacin.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Michaela G. Alewynse, Center for Veterinary Medicine (HFV-228), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6657.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) 21 U.S.C. 348(b)(5)), notice is given that a food additive petition (FAP 2239) has been filed by Vanetta S.p.A., Via Alzia Trento 10, Milano, Corsico, Italy. The petition proposes to amend the food additive regulations in part 573 *Food Additives Permitted in the Feed and Drinking Water of Animals* (21 CFR part 573) to provide for use of menadione nicotinamide bisulfite in swine diets as a source of vitamin K activity and niacin.

The agency has determined under 21 CFR 25.32 that this action is of the type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: April 24, 1998.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 98-12540 Filed 5-11-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### **Food Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

**Name of Committee:** Food Advisory Committee.

**General Function of the Committee:**

To provide advice and recommendations to the agency on FDA's regulatory issues.

**Date and Time:** The meeting will be held on June 15 and 16, 1998, 8 a.m. to

6 p.m.; and June 17, 1998, 8 a.m. to 1 p.m..

**Location:** Sheraton Reston Hotel, Grand Ballroom, 11810 Sunrise Valley Dr., Reston, VA.

**Contact:** Lynn A. Larsen, Center for Food Safety and Applied Nutrition (HFS-5), 202-205-4727, or Catherine M. DeRoeper (HFS-22), 202-205-4251, FAX 202-205-4970, Food and Drug Administration, 200 C St. SW., Washington, DC 20204, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 10564. Please call the Information Line for up-to-date information on this meeting.

**Agenda:** The committee will receive and undertake a scientific discussion about new data that have become available regarding the food additive olestra.

In the **Federal Register** of January 30, 1996 (61 FR 3118), FDA approved olestra for use as a food additive to replace conventional fats in prepackaged savory snacks. Olestra is a sucrose polyester formed with long chain fatty acids. The agency determined, based on its evaluation of the evidence in the record at that time, that there is a reasonable certainty that no harm will result from the use of olestra in savory snacks. At the time of approval, the petitioner, Procter and Gamble Co. (P&G), agreed to perform additional studies of olestra exposure (both amounts consumed and patterns of consumption) and the effects of olestra consumption. P&G also agreed to provide FDA with access to all data and reports of those studies as such information became available. At the time of olestra's approval, FDA committed to review all data received from P&G's studies, as well as any other new data that bear on the safe use of this additive, and present such information to the committee within 30 months of the approval.

Committee discussion will focus on data gathered from passive surveillance of complaints attributed to olestra consumption; the active surveillance of populations consuming savory snacks, including olestra snacks; any additional new data that have become available that bear on the safety of olestra (such as data and information on the health significance of carotenoids); and various other studies submitted by P&G (e.g., rechallenge, home consumption, and acute consumption test). The committee will consider whether these newly developed data are consistent with the original safety decision or whether the new data contradict FDA's original determination that there is a reasonable certainty of no harm from the use of

olestra in savory snacks. The committee will also discuss the bearing, if any, of these new data on the required label statement for olestra containing snacks.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 5, 1998. Oral presentations from the public will be scheduled in three sessions. The approximate session schedules and the topics upon which presentations at each should be focussed are: (1) Passive surveillance and special gastrointestinal studies on June 16, 1998, 8 a.m. to 9 a.m.; (2) active surveillance and new information on carotenoids on June 16, 1998, 4 p.m. to 4:30 p.m.; and (3) labeling on June 17, 1998, 10:30 a.m. to 11 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 5, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 4, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98-12449 Filed 5-11-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Council; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), announcement is made of the following National Advisory body scheduled to meet during the month of June 1998.

**Name:** Advisory Commission on Childhood Vaccines (ACCV).

**Date and Time:** June 10, 1998; 9:00 a.m.—5:00 p.m.; June 11, 1998; 9:00 a.m.—12:00 Noon.

**Place:** Parklawn Building, Conference Rooms G & H, 5600 Fishers Lane, Rockville, Maryland 20857.

The meeting is open to the public.

**Agenda:** Items will include, but not be limited to: an update on legislative proposals, an update on Vaccine Information Statements, an update on vaccines in clinical trials, an update on the Vaccine Adverse

Events Reporting System, an update on the Vaccine Safety Action Plan, and reports from the Department of Justice, the National Vaccine Program Office, and routine program reports.

Public comment will be permitted before lunch and at the end of the Commission meeting on June 10, 1998, and before adjournment on June 11, 1998. Oral presentations will be limited to 5 minutes per public speaker. Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Ms. Melissa Palmer, Principal Staff Liaison, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A-35, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-6593. Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. The Division of Vaccine Injury Compensation will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may sign-up in Conference Rooms G and H on June 10-11, 1998. These persons will be allocated time as time permits.

Anyone requiring information regarding the Commission should contact Ms. Palmer, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A-35, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-6593. Agenda items are subject to change as priorities dictate.

Dated: May 6, 1998.

**Jane M. Harrison,**

*Acting Director, Division of Policy Review and Coordination.*

[FR Doc. 98-12609 Filed 5-11-98; 8:45 am]

BILLING CODE 4160-15-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration (SAMHSA)

#### Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the following meeting of the SAMHSA Special Emphasis Panel I in May 1998.

A summary of the meeting and a roster of the members may be obtained from: Ms. Dee Herman, Committee Management Liaison, SAMHSA, Office of Policy and Program Coordination, Division of Extramural Activities, Policy, and Review, 5600 Fishers Lane, Room 17-89, Rockville, Maryland 20857. Telephone: 301-443-7390.

Substantive program information may be obtained from the individual named as Contact for the meeting listed below.

The meeting will include the review, discussion and evaluation of individual grant applications. These discussions could reveal personal information concerning individuals associated with the applications. Accordingly, this meeting is concerned with matters exempt from mandatory disclosure in Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App.2, § 10(d).

**Committee Name:** SAMHSA Special Emphasis Panel I (SEP I).

**Meeting Dates:** May 26-29, 1998.

**Place:** Residence Inn, Calvert Room, 7335 Wisconsin Avenue, Bethesda, MD 20815.

**Closed:** May 26-28, 1998 9:00 a.m.—5:00 p.m.; May 29, 1998 9:00 a.m.—adjournment.

**Panel:** Center for Mental Health Services Circles of Care.

**Contact:** Richard A. Peabody, Room 17-89, Parklawn Building, Telephone: 301-443-9919 and FAX: 301-443-3437.

Dated: May 6, 1998.

**Jeri Lipov,**

*Committee Management Officer, Substance Abuse and Mental Health Services Administration.*

[FR Doc. 98-12447 Filed 5-11-98; 8:45 am]

BILLING CODE 4162-20-P

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4369-N-01]

### Notice of Proposed Information Collection for Public Comment

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

**DATES:** Comments due: July 13, 1998.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Ms. Shelia Jones, Reports Liaison Officer, Office of the Assistant Secretary for Community Planning and Development, Department of Housing and Urban Development, 451-7th